Danimer Scientific downgraded to hold, price target cut to $1

On Monday, TD Cowen adjusted its stance on Danimer Scientific (NYSE: DNMR), shifting the stock rating from Buy to Hold. Accompanying this downgrade was a reduction in the price target, now set at $1, decreased from the previous target of $2. The revision follows projections of a slower than anticipated increase in activity at the company's Kentucky facility.

The firm's revised expectations are based on a more gradual escalation in operations at the Kentucky site, anticipated through 2025 and into 2026. Despite the downgrade, the firm acknowledged the strength of Danimer Scientific's core technology and expressed a constructive view on the company's recent initiatives to reduce costs.

The analyst stated that while they are optimistic about the company's technology and cost-saving measures, they anticipate the stock will remain relatively stable in the near term. This stability is expected until a significant uptick in the company's business is seen in the fiscal year 2026.

With the new price target of $1, the firm sets a cautious tone for investors, suggesting that any substantial growth in Danimer Scientific's business may not materialize until the latter part of the forecast period. The new hold rating indicates a neutral position on the stock's near-term performance.

The current assessment reflects a wait-and-see approach, as Danimer Scientific works towards a more pronounced business acceleration expected in fiscal year 2026. Investors are advised to monitor the company's progress, particularly concerning the ramp-up of its Kentucky facility operations.

In other recent news, Danimer Scientific, a bioplastics producer, has been notified by the New York Stock Exchange (NYSE) of its non-compliance with the exchange's minimum price standard. The company has expressed its intention to resolve this deficiency within the six-month grace period allowed by the NYSE. Meanwhile, Jefferies has downgraded Danimer Scientific's stock from a "Buy" to a "Hold" rating, adjusting its price target for the company to $0.80 from the previous $1.30. This change is attributed to the recent announcement of a CEO transition at Danimer Scientific without a clear successor.

InvestingPro Insights

As Danimer Scientific (NYSE: DNMR) faces a revised rating from TD Cowen, investors may benefit from additional context provided by InvestingPro. The company's market capitalization stands at a modest $47.07 million, reflecting the challenges it faces in the market. With a Price/Book ratio of 0.2 as of the last twelve months leading up to Q2 2024, Danimer Scientific is trading at a low multiple, which could suggest that its assets are undervalued relative to its stock price.

However, the financial data underscores some concerns. The company's Revenue Growth has declined by 21.4% over the same period, indicating shrinking sales, and a significant Gross Profit Margin deficit of -61.46% suggests that the company is not only making a loss on its products but also burning through cash quickly. This is further evidenced by the company's negative Operating Income Margin of -249.83%. These figures may give investors pause, considering the company's near-term prospects.

InvestingPro Tips highlight that analysts have recently revised their earnings expectations downwards for Danimer Scientific, and the company is not expected to be profitable this year. Additionally, with a Price/Earnings (P/E) ratio of -0.32, the company's earnings are negative, which may be a red flag for potential investors. According to InvestingPro, there are 15 additional tips for Danimer Scientific that could offer further insights, accessible at: https://www.investing.com/pro/DNMR.

Given these financial metrics and the InvestingPro Tips, investors may wish to closely monitor Danimer Scientific's performance, especially as it pertains to the ramp-up of its Kentucky facility, which is anticipated to be a significant driver of future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.